{"id":"NCT00918957","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2009-06-11","resultsPosted":"2012-10-03","lastUpdate":"2012-10-03"},"enrollment":62,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Tobramycin Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TIP (Tobramycin Inhalation Powder)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to show how well tobramycin inhalation powder works and how safe it is when produced by a modified manufacturing process","primaryOutcome":{"measure":"Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to End of Dosing (Day 29)","timeFrame":"Baseline, Day 29","effectByArm":[{"arm":"TIP (Tobramycin Inhalation Powder)","deltaMin":8.2,"sd":2.93},{"arm":"Placebo","deltaMin":2.3,"sd":3.13}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":22},"locations":{"siteCount":24,"countries":["Bulgaria","Egypt","Estonia","India","Latvia","Lithuania","Romania","Russia","South Africa"]},"refs":{"pmids":["23672633"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Hypoacusis","Respiratory tract infection viral","Cough","Respiratory tract infection"]}}